Table of contents
Intracerebral hemorrhage
What's new
The European Stroke Organisation (ESO) and the European Association of Neurosurgical Societies (EANS) have updated their guidelines for the management of spontaneous intracerebral hemorrhage (ICH). In VKA-associated ICH, reversal should include prothrombin complex concentrate combined with IV vitamin K to normalize and stabilize the INR. For factor Xa inhibitor-associated ICH, prothrombin complex concentrate is suggested. Andexanet alfa can be considered within 12 hours of symptom onset and 15 hours of the last dose, or when anti-FXa activity is elevated. In dabigatran-associated ICH, immediate administration of idarucizumab is suggested. In patients with minor or moderate ICH (hematoma volume <30 mL), lowering systolic blood pressure to below 140 mmHg within 6 hours of symptom onset is recommended to reduce hematoma expansion. However, systolic pressure should not be reduced by more than 70 mmHg from baseline or lowered below 110 mmHg. The guidelines recommend against several isolated interventions, including intensive glucose control, primary antiseizure prophylaxis, and anti-inflammatory or neuroprotective agents such as corticosteroids, anakinra, and minocycline. .
Guidelines
Key sources
Classification and risk stratification
Diagnostic investigations
More topics in this section
Diagnostic imaging (CT/MRI)
Diagnostic imaging (CTA/MRA)
Diagnostic imaging (digital subtraction angiography)
Medical management
More topics in this section
Prehospital care
Management of BP
Management of blood glucose
Management of coagulopathy (discontinuation of anticoagulation)
Management of coagulopathy (VKA-induced)
Management of coagulopathy (factor Xa inhibitor-induced)
Management of coagulopathy (direct thrombin inhibitor-induced)
Management of coagulopathy (heparin-induced)
Management of coagulopathy (antiplatelet-induced)
Management of coagulopathy (rFVIIa)
Management of coagulopathy (tranexamic acid)
Management of coagulopathy (ciraparantag)
Thromboprophylaxis
Management of ICP (monitoring)
Management of ICP (ventricular drainage)
Management of ICP (hyperosmolar therapy)
Management of ICP (corticosteroids)
Seizure prophylaxis
Management of seizures
Management of body temperature
Anti-inflammatory agents
Management of comorbidities
Withdrawal of care
Inpatient care
More topics in this section
Imaging monitoring
Prevention of inpatient complications
Nonpharmacologic interventions
Surgical interventions
More topics in this section
Indications for surgery (cerebellar hemorrhage)
Indications for surgery (intraventricular hemorrhage)
Specific circumstances
More topics in this section
Patients with concomitant VTE
Patient education
Preventative measures
More topics in this section
Secondary prevention
Follow-up and surveillance
More topics in this section
Management of neurobehavioral complications
Follow-up imaging
Long-term medical therapy (resumption of antithrombotics)
Long-term medical therapy (management of BP)
Long-term medical therapy (statin therapy)